Your session is about to expire
← Back to Search
Study Summary
This trial tests a drug for relapsed or refractory mantle cell lymphoma to assess safety, tolerability, and efficacy.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My organs are working well.I have a serious heart condition.My diagnosis of mantle cell lymphoma is confirmed by tissue analysis.My condition has returned or didn't respond to treatment.I have had treatments for MCL including anti-CD20 therapy and a BTK inhibitor.I can provide tissue samples for my mantle cell lymphoma diagnosis.I am currently being treated for a serious infection.My lymphoma has spread to my brain or spinal cord.I have not had major surgery or a significant injury in the last 4 weeks.My cancer can be measured by tests.I can care for myself and am up and about more than 50% of my waking hours.I haven't had cancer in the last 3 years, except for certain non-aggressive types or skin cancer.I had a stem cell transplant or CAR T-cell therapy recently, or I'm currently on immunosuppressants for graft-vs-host disease.I have been treated with a BCL-2 inhibitor before.
- Group 1: Single Arm
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants has this experiment attracted thus far?
"Confirmed. The clinical trial is open for enrollment and the details posted on clinicaltrials.gov were last edited on January 23rd 2023. Currently, 98 participants are needed from a single site."
What potential perils do patients face when participating in a Single Arm program?
"According to our evaluation, the safety rating of Single Arm is set at a 2 due its Phase 2 status. This implies that while there are some indications of safety, efficacy has yet to be established."
Is this investigation still enrolling participants?
"According to clinicaltrials.gov, this trial is recruiting patients at the present time. The study was first uploaded on September 5th 2022 and recently updated on January 23rd 2023."
Share this study with friends
Copy Link
Messenger